Makers of Humira and Enbrel Using New Drug Patents to Delay Generic Versions

The best-selling drugs Humira and Enbrel have a lot in common. They both use biotechnology to treat rheumatoid arthritis, psoriasis and other autoimmune diseases. And they come with giant price tags approaching $50,000 a year.

It may be essentially equivalent to a scientist or an insurance company, but it’s not to the patient,” said Seth Ginsberg, president of the Global Healthy Living Foundation, a patient advocacy group.

Click here to read the full article